Scarica l'app Stockscreener
145.13
8.86%
11.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$133.32
Aprire:
$133.11
Volume 24 ore:
87.01M
Relative Volume:
7.26
Capitalizzazione di mercato:
$57.94B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-17.82
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+129.20%
1M Prestazione:
+143.26%
6M Prestazione:
+191.02%
1 anno Prestazione:
+453.51%
Intervallo 1D:
$132.42
$159.47
Intervallo di 1 settimana:
$62.13
$176.66
Portata 52W:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna cancer vaccine breakthrough revives hopes for biotech turnaround By Investing.com - Investing.com Nigeria
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Health Care Up as Moderna Leads Biotech HigherHealth Care Roundup - marketscreener.com
Moderna Shares (NASDAQ:MRNA) Finish Landmark Week, Surging 70% Over Wall Street Consensus - TechStock²
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
Moderna Soars 129% for the Week | Closing Bell - marketscreener.com
Moderna Stock Erupts As Cancer Vaccine Trial Delivers Historic Win - StocksToTrade
Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits - timothysykes.com
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market - Barron's
Bessent's Bond Rescue, Bitcoin's Best Week Since 2023Coinbase Global (NASDAQ:COIN) - Benzinga
Moderna (MRNA) Cancer Vaccine Success Won’t Lift All mRNA Stocks - Barron's
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet. - Barchart.com
Moderna’s Cancer Vaccine Breakthrough Sends Stocks Soaring - cheddar.com
Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far - Barron's
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now - TradingView
Moderna Stock Explodes As Landmark Cancer Trial Sparks Re‑Rating - StocksToTrade
Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough - timothysykes.com
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink - WSJ
Moderna (NASDAQ:MRNA) Price Target Raised to $77.00 at JPMorgan Chase & Co. - MarketBeat
After Moderna’s Big News, Here Are Three Biotechs to Watch - TheStreet Pro
Moderna Inc Stock (MRNA) Moved Up by 14.01% on Aug 21: What Signal Does It Send? - TradingKey
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Moderna jumps 18% on investor optimism - Breakingthenews.net
Moderna Options Flash Extreme Caution as Cancer Vaccine Fuels Stock Surge: Options Chatter - Moomoo
Moderna Cancer Vaccine Could Redefine the CompanyModerna (NASDAQ:MRNA) - Benzinga
Moderna (NASDAQ:MRNA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session - Yahoo Finance
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial - KXAN Austin
Rx Rundown: Moderna, Merck, LEO Pharma and more - Medical Marketing and Media
Moderna’s 177% Surge Has Investors Asking What Comes Next - MarketBeat
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped - MarketWatch
Moderna and Merck cancer vaccine success paves way for future - EMJ
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’ - Yahoo Finance
Meeder Advisory Services Inc. Buys New Shares in Moderna, Inc. $MRNA - MarketBeat
MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure - TradingView
A Cancer Vaccine Is Closer Than Ever - Bloomberg.com
Amid the chip bear market, healthcare is breaking out: Chart of the Day - Yahoo Finance
JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating - marketscreener.com
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED) - Yahoo Finance
Personalized cancer vaccine launched by Moderna: Drug firm’s shares soar more than 100% — should you buy? - Yahoo! Finance Canada
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
983,450 Shares in Moderna, Inc. $MRNA Bought by Deutsche Bank AG - MarketBeat
Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In? - Yahoo Finance
5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go - CryptoRank
Watch Moderna, Merck Cancer Vax Gives Hope - Bloomberg.com
Moderna, Merck develop vaccine that could help fight against melanoma - cbs8.com
Moderna (MRNA) Sees Stock Surge After Positive Melanoma Trial Re - GuruFocus
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead - Yahoo Finance
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):